The novel dual BET/HDAC inhibitor TW09 mediates cell death by mitochondrial apoptosis in rhabdomyosarcoma cells
- 20 May 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 486, 46-57
- https://doi.org/10.1016/j.canlet.2020.05.008
Abstract
No abstract availableFunding Information
- BMBF
- Structural Genomics Consortium
This publication has 44 references indexed in Scilit:
- Small Molecule Inhibitors of Zinc-dependent Histone DeacetylasesNeurotherapeutics, 2013
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid TumorsClinical Cancer Research, 2013
- Malignant ectomesenchymoma in children and adolescents: Report from the Cooperative Weichteilsarkom Studiengruppe (CWS)Pediatric Blood & Cancer, 2012
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- A phase 2 study of vorinostat in acute myeloid leukemiaHaematologica, 2009
- A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and LymphomasClinical Cancer Research, 2008
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapyOncogene, 2006
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005